No conflicts of interest were declared.
In Brief: BRCA1 and BRCA2
Article first published online: 9 JUL 2013
Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
The Journal of Pathology
Volume 230, Issue 4, pages 347–349, August 2013
How to Cite
Foulkes, W. D. and Shuen, A. Y. (2013), In Brief: BRCA1 and BRCA2. J. Pathol., 230: 347–349. doi: 10.1002/path.4205
- Issue published online: 9 JUL 2013
- Article first published online: 9 JUL 2013
- Accepted manuscript online: 25 APR 2013 06:48AM EST
- Manuscript Accepted: 16 APR 2013
- Manuscript Received: 14 APR 2013
- breast cancer;
- ovarian cancer;
- DNA repair;
- triple negative;
- targeted therapy;
The discovery of the first major breast cancer susceptibility gene, BRCA1, occurred almost 20 years ago. BRCA1, together with BRCA2 remain the most important discoveries in human cancer genetics. Identification of highly penetrant mutations in these two tumour suppressor genes has had broad implications for women at risk and their families, for health professionals caring for these persons and for basic researchers. The BRCA proteins have many critical functions, the most notable of which, from a clinical perspective, is repair of double-strand DNA breaks. Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.